Multiple PIs

The move, caused by frustration with US stem cell policy, may bode poorly for the future of American efforts in this field, experts say

FEATUREBest Places to Work 2006: Industry   Courtesy of Transform PharmaceuticalsWhat makes a company a great place to work? In our fourth annual survey, industry scientists share their insights.BY KAREN PALLARITOBrian Hopkins, a PhD research scientist and project leader at Infinity Pharmaceuticals, joined the Cambridge, Mass., company in May 2002 partly because he liked its DOS (diversity-oriented synthesis

To intramural scientists at the US National Institutes of Health whose endgame is being published, scrawled notations, E-mail exchanges and antiquated lab instruments are the flotsam and jetsam of research. But to Victoria A. Harden, founder of the Office of NIH History, these materials are gold. "The American people were putting billions of dollars into the NIH and they were getting a tremendous product for the money, and nobody knew about it," says the 62-year-old Ha

Louisiana scientists say the interim threat from Katrina is real and could cause further setbacks, layoffs

Employees at Bayer Biological Products in Berkeley, Calif., throw a party once a year celebrating their diverse cultural backgrounds.

Throughout much of his career, Tin-Chuen Yeung has straddled two worlds within the life sciences: bench science and business development.

Keith Miller, a 31-year-old supervisor of fill operations in the clinical production unit of Berlex, the US affiliate of Schering AG Germany, never imagined his nearly 2-year-old twins would end up in body casts.

In a recent three-hour session at a Chicago hotel room, the University of Wisconsin's technology transfer office hammered out the final details of licensing deal that granted Durham, NC-based Inspire Pharmaceuticals the right to use several patents to develop glau coma treatments.

PINNING THE BLAME:© 2004 New England Journal of MedicineCurrent and emerging Alzheimer Disease treatment options hinge on the hypothesis that amyloid β (Aβ), created by the sequential cleavage of amyloid precursor protein (APP), is the culprit behind neurodegeneration and associated cognitive and behavioral abnormalities. This could occur through multiple pathways. (Reprinted with permission from N Engl J Med, 351:56, 2004.)Neuroscience has made impressive strides since 1936 Nobel

World RNAi Market 2010Contract service = outsourced research/target validation projects Total = Projected worldwide RNAi revenues for 2010, in US dollars Source: Frost & SullivanScientists hunger for breakthroughs in the lab, but it's the venture capitalists who continually scout the life sciences for the next great money-making bonanza. After a pivotal study in the May 2001 issue of Nature showed that RNA could effectively silence gene expression in mammalian cell lines, RNA interference (R